<DOC>
	<DOCNO>NCT01479868</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability TMC435 along pegylated interferon alpha-2a ( PegIFNα-2a ) ribavirin ( RBV ) triple therapy hepatitis C virus genotype-1 infected subject , co-infected human immunodeficiency virus-type 1 , evaluate number patient sustain virologic response ( SVR ) 12 week planned end treatment .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability Efficacy TMC435 Along With Pegylated Interferon Alpha-2a ( Pegasys ) Ribavirin ( Copegus ) Triple Therapy Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single arm ( study conduct single group ) clinical study , evaluate safety , tolerability efficacy TMC435 along pegylated interferon alpha-2a ( PegIFNα-2a ) ribavirin ( RBV ) triple therapy adult chronic hepatitis C ( CHC ) genotype-1 infected patient co-infected human immunodeficiency virus-type 1 ( HIV-1 ) . The study consist 3 phase , screen phase ( Week -6 ) , treatment phase , follow-up phase ( 24 week ) . In treatment phase , patient classify base experience previous hepatitis C virus ( HCV ) treatment follow : 1 ) HCV treatment-naive ( patient never receive medication treatment HCV ) ; 2 ) prior HCV relapsers ( patient receive least 24 week PegIFNα-2a RBV-based therapy relapse within 1 year last medication intake ) ; 3 ) prior HCV non-responders ( classify , null responder : patient least 1 prior documented course PegIFNα-2a RBV therapy least 12 consecutive week ; partial responder : patient least 20 consecutive week discontinue due intolerability PegIFNα-2a RBV therapy ) . All patient receive TMC435 daily along PegIFNα-2a RBV 12 week . Patients continue treatment PegIFNα-2a RBV follow 24 48 week . Pharmacokinetics measure collection blood sample . Safety evaluation adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination , specific toxicity perform throughout study . The total duration treatment approximately 24 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>A liver biopsy require within 3 year prior screen unless patient contraindication liver biopsy Patients bridge fibrosis cirrhosis without liver biopsy result within 2 year prior screen must ultrasound take within 2 month prior screen visit screen finding suspicious hepatocellular carcinoma ( HCC ) Genotype1 hepatitis C virus ( HCV ) infection Plasma HCV ribonucleic acid ( RNA ) 10,000 IU per mL Documented human immunodeficiency virustype 1 ( HIV1 ) infection least 6 month prior screen Patient show evidence hepatic decompensation ( ie , history current evidence ascites , bleed varix hepatic encephalopathy , albumin serum concentration le 3.3 gm per dL , prolong prothrombin time [ PT ] express international normalized ratio [ INR ] 1.5 ) Any liver disease nonHCV etiology Coinfection hepatitis B virus ( hepatitis B surface antigen [ HBsAg ] positive ) An acute HIV1 infection ; HIV2 infection Change antiretroviral ( ARV ) regimen within last 4 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Hepatitis C virus genotype-1</keyword>
	<keyword>Human immunodeficiency virus-type 1</keyword>
	<keyword>HCV-1</keyword>
	<keyword>HIV-1</keyword>
	<keyword>TMC435</keyword>
	<keyword>Pegylated interferon alpha-2a</keyword>
	<keyword>PegIFNα-2a</keyword>
	<keyword>Pegasys</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>RBV</keyword>
	<keyword>Copegus</keyword>
</DOC>